Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Inventory: 2021-2024

Historic Inventory for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $26.4 million.

  • Kiniksa Pharmaceuticals International's Inventory rose 44.34% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year increase of 44.34%. This contributed to the annual value of $26.4 million for FY2024, which is 15.29% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Inventory stood at $26.4 million for FY2024, which was down 15.29% from $31.1 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Inventory registered a high of $31.1 million during FY2023, and its lowest value of $3.7 million during FY2021.
  • Moreover, its 3-year median value for Inventory was $26.4 million (2024), whereas its average is $26.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Inventory spiked by 487.73% in 2022 and then declined by 15.29% in 2024.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Inventory stood at $3.7 million in 2021, then spiked by 487.73% to $21.6 million in 2022, then soared by 44.09% to $31.1 million in 2023, then decreased by 15.29% to $26.4 million in 2024.